Dr. Kathy High, President and Head of Research and Development, and Federico Mingozzi, Chief Scientific Officer, in the Spark Therapeutics laboratory
Research scientists in the Spark Therapeutics laboratory
Dr. Kathy High, President and Head of Research and Development, and Federico Mingozzi, Chief Scientific Officer, in the Spark Therapeutics laboratory
Employees in the Spark Therapeutics office

We don’t follow footsteps. We create the path.

News & events

Spark Therapeutics Wins Prix Galien USA Award The Galien Foundation has awarded Spark Therapeutics with the prestigious 2019 Prix Galien USA Award for "Best Biotechnology Product"

Read More read more

Science Magazine Names Spark 2019 Top Biotech and Pharma Employer Spark Therapeutics ranks fifth on a list of 20 admired Top Employers in the field

Read More read more

Definitive Merger Agreement with Roche Deal expected close in 2019; Spark Therapeutics to continue operations in Philadelphia as an independent company within the Roche Group

Read More read more

Get our news alerts delivered straight to your inbox

Subscribe Now

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-directed diseases such as hemophilia, and neurodegenerative diseases.

Learn More